Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00511771
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2010-11-18
First Post:
2007-08-03
Brief Title:
A Treatment Investigational New Drug tIND Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Treatment Investigational New Drug tIND Program of Tegaserod 6 mg Bid Given Orally in Women Adult Patients With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To provide tegaserod to eligible women adult patients who did not have satisfactory improvement of their irritable bowel syndrome with constipation IBS-C or chronic idiopathic constipation CIC symptoms with other available treatments and or patients who had satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None